c
cc





c
 c




 
 c 







c


c


 established Dr. Reddy¶s Laboratories in 1984. As a fully integrated
pharmaceutical company, its purpose is to provide affordable and innovative medicines through three
core businesses:
i. Pharmaceutical Services and Active Ingredients, comprising Active Pharmaceuticals
and Custom Pharmaceuticals businesses;
ii. Global Generics, which includes branded and unbranded generics; and
iii. Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated
Formulations, and Generic Biopharmaceuticals.

Dr. Reddy's Laboratories Ltd., trading as Dr. Reddy's is India's second biggest pharmaceutical
company. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and
overseas. The company has over 190 medications, 60 active pharmaceutical ingredients for drug
manufacture, diagnostic kits, critical care, and biotechnology products.

Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other
less-regulated markets that had the advantage of not having to spend time and money on a
manufacturing plant that that would gain approval from a drug licensing body such as the U.S. Food
and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these
unregulated markets enabled the company to begin focusing on getting approval from drug regulators
for their formulations and bulk drug manufacturing plants in more-developed economies. This allowed
their movement into regulated markets such as the US and Europe.

By 2007, Dr. Reddy's had six FDA-plants producing active pharmaceutical ingredients in India and
seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified
plants making patient-ready medications ± five of them in India and two in the UK.

 
 

  



 

Dr. Reddy¶s Laboratories was incorporated on 
!"#
$%&'. The Company was promoted by
c


 and his associates who were also the promoters of ())
*)+,-
(. In
May 1985, the Company issued .-/0-000
12(
,3), of ,
$0
)+3 for cash at par linked to
$-/0-000

$/4
,+2
")#5
 + !(#5
#(2,
6
,
$00
)+3
6 
+),3
)(
7) in
the proportion of one debenture for 6!
12(
,3), held including the oversubscription from the
public. The allotment was made as follows-
(i) $-//0
12(
,3),
58
(
-/$0
#(2, were issued to
#2,,,
),, +)(,
(ii) &/0
,3),
58
(
$.0
#(2, were issued to the
"75 ,
(iii) -&0-/00
,3),
58
(
/9-$00
#(2, issued to the
 ,(
), and


(iv) /-/-&/0
,3),
58
(
$-0/-$.0
#(2, were issued to the 72#5+.
In 1986 the company issued the following equity shares-
A.$0-09-/00
12(
,3), then issued at par out of which
a. -/9-/00
12(
,3), were ,! and allotted to 7 " (,-
(+
b. :-/-/00
12(
,3), 58
(
#(2,
were reserved for preferential
allotment-
(i) $/-000
,3), to #2,,,
),, +)(, of the Company (only $-//0
,3),

()8
27);
(ii) :.-/00
,3), to "75 ,
of the company (only &/0
,3),
()8
27)
(iii) :-00-000
,3), to  ,(
), (only -&0-/00
,3),
()8
27.
and
 c. The balance :-%.-/00
,3), along with the 2,2#,+#
7 ( 
6
/&-900

,3), out of the 76()5
12 () were 66
6 
72#5+ subscription during
June.
B. $-$9-/0
)( )5
,3), 58
(
#(2, were )55 ((
(
()
!,2#,+7( 



'9-/00 shares to 7 " (, and
ii 9%-./0
,3), to the 72#5+



In 1988 the company decided to 6 6(
$:-990-/00
2"# of 12(
,3), A plan was
also drawn for the expansion and modernisation of formulations division.  and  sanctioned
("
5 ), of ,
$%&
5)83, and ,
$:
5)83,
,7+(!5.

In 1989 the company decided to issue 9-&:-$/
*3(,
,3),
)(
)
7"2"
6

,
$/
7
,3)
)


7 7 ( 
6
$v. An Additional $-0-'.0
,3),
;
allotted to ()
!,2#,+7( 

Another :'-$//
,3),
)(
)
7"2"
6
,
$/ 7
,3)
; allotted to "75 ,.

The company issued $0-%-%/0
# 2,
12(
,3), in 7 7 ( 
(
$v

$%%$
) :-.&-&/0

# 2,
12(
,3), in 7 7 ( 
(
$v$

$%%

A ,7))(
+ "7) in the name of <c
=,
c* ,(+,
( was set up in 1993 for the
manufacture of diagnostics kits. The Company decided to !(
904

(3
12(
+)7()5
6
(3

+ "7).

The Company, in 1994, invested in  "7)+(
5+(+
(., which was in the process of setting up a
plant at Chennai for manufacturing energy efficient electric filament/discharge lamps in Collaboration
with Li-Tech Corporation, South Korea. The Company set up a subsidiary < 
 *
 *
(.'
in Hong Kong for marketing the Company's products in Main Land China and Far East countries. In
the same year a joint venture in the name of ` 
 "
(.' was formed with a Russian
Company `> (
( +8
 "7)
6
7
(7
)"
)6(
$?$

)+38 != for manufacturing and
marketing formulation in Russia. ())
12(
2 was "*
with the Company with
effect from 1st April 1994. Pursuant to the scheme of )")5*)")(  -9:-09
12(
,3),
6
,

$0
)+3
6
(3
 "7) were issued to the shareholders of erstwhile ())
12(
2 in the
)( of 
12(
,3)
6
(3
 "7)
6 
(
12(
,3),
6
(3
,(;35
())
12(

2
(. During July, 1994 the Company issued ':0$0.9
5 #)5
c7 ,( 
+7(, at )
7+
6


$9
7
c . The Company allotted ':0$0.9
12(
,3),
6
,
$0
)+3
)(
)
7"2"
6
,

:'0
7
,3) underlying the GDRs. It further issued '-:0$-0.9
c, representing '-:0$-0.9
12(

,3), of the Company, par value ,$0
@3),A- in a 7!)(
75)+"( in 1994 pursuant to
Regulation S and Rule 144A under the Securities Act of 1933 (the Securities Act). The GDSs are
listed on the Luxembourg Stock Exchange and each GDS represents one Share. As of May 4, 2001,
there were $-.&%-&/
c,
outstanding representing $-.&%-&/
3),. Pursuant to the scheme of
amalgamation 9:-09
12(
,3),
;
,,2 in 1995 to the shareholders of ,(;35
,())

12(
2
(.

c
=,
)# )( ,, in 1997, formed (; new  (
!(2, in Brazil and Uzbekistan. It


+
(
"*
3" 
c2*,
"(
@cA
;(3
the ,;)7
)( at 
,3),
6
6 
/

,3),
6
3"  in 1998 which was approved by the Board in 2000. The Company decided to
issue .-/0-000
12(
,3), under  
This made the company third largest pharmaceutical
company in India. c
=,
)# )( , signed a joint venture agreement in 1999 with the
3()
* 27-
7)5, for setting up a  (
!(2 for the manufacture and marketing of finished
formulations in Nepal and other neighbouring countries.Dr. Reddy's Laboratories again in 2000 signed
a memorandum of understanding with ##5,
 27
6
2,()5) to form a  (
!(2
company for establishing a network of 50 pathology laboratories and up to 200 specimen collection
centres in India over the next five years.
In April 2001, Dr. Reddy's Laboratories began trading on the ;
 8
( +8
B+3)* (code:
              Y     
  
Y
  
                    
   
      
 

RDY). The price to the public per ADS was .04. Total amount raised (net) was $ 124 million. In May
2001, the company decided to terminate the GDS programme.

c
=,
)# )( ,
announced )
! of ,
/0 on equity share of Rs 5 each in 2002. It
granted 1813 stock options to an employee of the Company at the meeting of the Compensation
Committee of Board of Directors held on August 26, 2002. The options were granted at a price of Rs
884 per option, which was equivalent to weighted average share price of the Company of last 30 days
on BSE. It further granted 2,59,400 stock options under ESOP (Employee Stock Option Plan). In 2002
Promoters holding slept from 31.5% to 26%.

With the approval of the Board c
=,
)# )( ,
"* Zenovus Biotech Ltd., a wholly
owned subsidiary in 2003. In the same year it )+12
US firm
*,,
After five years of
silence it )+12 >(
+
, a Company engaged in the sale of generic finished dosages in
Italy in 2008. In the same year it )+12 's pharmaceutical contract manufacturing business
and related facility in Shreveport, Louisiana, USA. Statements showing shareholding patterns as of
31st March 2010 are given below ±

?
?


? 

?

       
  
 

   
    
   

 Y    !  !  "  

  #

V
 
          

V
   !"  !V

       

V#
 $!
!%!     & &  &

V
  # 

!
$ '
       

V
 ()*V
%#+
       

Y$   & &  &&  

% &  

V
 
V,-
!.

       

V
 $!
!%!        

V#
 
!
       

V
 ()*V
%#+
       

Y$%       

Y    !  !  

 & &  &&  
" ' % 

!    

 #

V
 / 
 0 & &  && & ,( ,(

V
  # 

!
$ '
  &    ,( ,(

V#
   !"  !V

      ,( ,(

V
 1 % 

      ,( ,(

V
 
 #!% 
  & &   ,( ,(

V+
 !.
! 
!
  & &  && ,( ,(

V.
 !.1 % 

!
      ,( ,(

V*
 ()*V
%#+
       

Y$   && &&   ,( ,(

%$

V
 $!
!%!   &   & ,( ,(

V
 


 
* *! 
*! .
V
  &&& &   ,( ,(
! 
* # % %!-
 '*

 
* *! 
*! .
V
 ! 
* # % 2#

!+-
   & &  ,( ,(
 '*

V#
 ()*V
%#+


  ./
    &  ,( ,(

!., !       ,( ,(

,-  & &  & ,( ,(

Y$% & & &   ,( ,(

!Y    ' %  & &&& &   ,( ,(

() &  &&    

Y   

    *
+      ,( ,(
,

"+*() -./ 0 1//234/3 134%.3%.  ..
.. %%%3...
4%

 ?


? 



 



?



?



    Y       
Y
      
  Y        
       5

6"        " 
Y 
 #,7

=
 =
     


  =  =   

    =   = = 

  =      


  = =  =   


  ==   =   


  ==   =   


  =      

   
     

=   ===     

==    =  =   

=  ! "#$ %  = =    

=  ! "#$ % 

 =  =   = 

? 
 

 
 


?


? 



 



?



?
 


?



?


?

Y
    Y       5

6" 
     
    Y #,7 

= &'&'&  %( &) '# =

  = =

 * * &+ #  = 

 , - , ./ 0( 12 %  = = 

" 3' , '#2 % =  

 ".'
#* &+ 3  

 %( &) '#2## 0( & ==

== =

?   
 


?


?






!"


      Y   
  *+  
 
Y
 *+*+6"*+6  
      5

6" 
 *+
Y*+6
 *+ Y #,7 

=     
  
= 

?


 


?


 






!"#

 


?
?


$




?


?


 *+     Y   
  *+  
 *+
Y
 *+6"*+6Y*+6  
     5

6" *+
 

   Y #,7 

= .#4 .#   == =

 12)*   = 
 = 

?

 




c 
C
> 

D
 

1. Aurigene Discovery Technologies (Malaysia) SdnBhd

2. Aurigene Discovery Technologies Inc.
3. Aurigene Discovery Technologies Limited
4. beta institute fursozialmedizinische Forschungund Entwicklung GmbH
5. Beta Healthcare Solutions GmbH
6. Betapharm Arzneimittel GmbH
7. Cheminor Investments Limited
8. Chirotech Technology Limited
9. Dr Reddy's Bio Sciences Limited
10. DR SLLC
11. Dr. Reddy¶s Farmaceutica Do Brazil Ltda.,
12. Dr. Reddy¶s Laboratories (Australia) Pty Ltd
13. Dr. Reddy¶s Laboratories ILAC TICARET Limited SIRKETI
14. Dr. Reddy¶s Laboratories Louisiana LLC
15. Dr. Reddy¶s LaboratoriesInc.,
16. Dr. Reddy's Laboratories (EU) Limited,
17. Dr. Reddy's Laboratories (Proprietary) Limited
18. Dr. Reddy's Laboratories (UK) Limited,
19. Dr. Reddy's Laboratories International SA
20. Dr. Reddy's Laboratories Limited
21. Dr. Reddy's Laboratories SA
22. Dr. Reddy's Newzealand Limited
23. Dr. Reddy's Pharma SEZ Limited
24. Dr. Reddy's S.r.l
25. DRL Investments Limited
26. Eurobridge Consulting B.V
27. Idea 2 Entreprises (India) Private Limited
28. Industrias Quimicas Falcon De Mexico SA de CV
29. JV Reddy Biomed Limited,
30. Kunshan Rotam Reddy Pharmaceutical Company Limited
31. Lacock Holdings Limited
32. Macred India Private Limited
33. Promius Pharma LLC
34. Reddy Antilles N.V.,
35. Reddy Cheminor S.A.,
36. Reddy Holding GmbH
37. Reddy Netherlands B.V.
38. Reddy Pharma Iberia,S.A.
39. Reddy Pharma Italia S.p.A
40. Reddy Pharmaceuticals HongKong Limited,
41. Reddy US Therapeutics Inc.
42. Trigenesis Therapeutics Inc.

***********************